8 Biobanking and Sample Management Providers in 2026

A biobanking service provider stores, tracks, and manages the biological samples a clinical trial generates, from blood and tissue to plasma and cell lines, keeping them viable and traceable often for years after a study ends. This kind of clinical sample logistics vendor ranges from automated cold-chain storage and biorepository operators, to central labs coordinating sample collection and testing across multi-site trials, to device makers building simpler ways to collect a sample in the first place.

The companies below are listed in no particular order. Between them, these companies and providers cover automated cryogenic biorepository storage, human biospecimen marketplaces, central laboratory and clinical kitting services, global cold-chain sample logistics, and patient-centric blood collection devices.

Azenta Life Sciences

Azenta Life Sciences was created in 2021 when Brooks Automation rebranded its Life Sciences Services and Products division, separating the business from Brooks' semiconductor equipment operations (later sold to Thomas H. Lee Partners) to focus entirely on sample management and genomic services. Headquartered in Chelmsford, Massachusetts with roots tracing to 1981, the company provides cold-chain sample management, biobanking, automated storage systems, and biorepository services for drug development, clinical research, and advanced cell therapy programs. Azenta's BioArc Ultra automated storage system and patented cryogenic freezers and shippers are built to preserve sample integrity across the cold chain, while its Limfinity software manages lab workflow and bio-sample data digitally. The company, now publicly traded as Azenta, Inc. (Nasdaq: AZTA), also owns AskBio's gene therapy technology assets and continues to expand its automated biobanking infrastructure for pharmaceutical, biotech, and academic institutions globally.

Central BioHub

Central BioHub operates what it describes as the world-leading online marketplace for human biospecimens, founded in 2017 by a group of scientists who had personally experienced how time-consuming biospecimen procurement could be for research projects. The Hennigsdorf, Germany-based company connects researchers, pharmaceutical companies, and diagnostic labs with an inventory that has grown to more than 800,000 biospecimens, including serum, plasma, whole blood, and FFPE tissue samples sourced from more than 50 suppliers worldwide. Central BioHub's platform lets customers filter its inventory by clinical diagnosis, ICD-10-CM codes, and laboratory parameters, reducing biospecimen acquisition times the company says once took months down to minutes. The company also supports suppliers with standardizing sample data, informed consent documentation, and legally compliant restrictions on how donated biospecimens can be used in research.

Crioestaminal

Crioestaminal was founded in 2003 by researchers from the University of Coimbra as the first cord blood bank to operate in the Iberian Peninsula, cryopreserving umbilical cord blood and tissue stem cells for private family storage at its purpose-built laboratory in Biocant Park. The company became the first cryopreservation laboratory in Portugal authorized by the country's health authorities, and in 2010 became the only laboratory in Iberia accredited by AABB (the Association for the Advancement of Blood & Biotherapies). Crioestaminal has been part of the Famicord Group, Europe's largest cord blood banking network, since 2018, and now holds an inventory serving more than 120,000 families along with an Infarmed-certified GMP manufacturing capability for cell-therapy medicinal products. While Crioestaminal's core business is private family stem cell storage rather than clinical trial sample logistics specifically, its parent Famicord Group is currently running late-phase clinical trials using mesenchymal stem cells derived from cord tissue for conditions including epidermolysis bullosa and muscular dystrophy.

GenVault

GenVault was founded in 2020 by Keith DiMarino, who had spent nearly two decades building DocuVault, a secure document and records storage company, before recognizing a similar unmet need for secure biological material storage among his life sciences clients. Based in West Deptford, New Jersey, sharing a half-million-square-foot, purpose-built campus with its sister company DocuVault, GenVault stores biological materials, GxP supplies, cell and gene therapy cell lines, finished drug products, vaccines, and high-value equipment for academic institutions, pharmaceutical companies, and government clients. The company offers customizable storage conditions ranging from ambient to cryogenic (-196°C, liquid nitrogen), with flexible interior layouts that let clients scale their storage footprint up or down as needs change rather than being locked into fixed lab space costing up to $700 per square foot. GenVault Transportation extends the company's services into moving freezers and biological materials, at temperature, across town or across the country.

KCAS Bio

KCAS Bio is a global bioanalytical contract research organization with more than 45 years of experience supporting drug development from early discovery through regulatory approval, having contributed to more than 315 drug approvals currently on the market. The company's Kansas City headquarters spans a purpose-built, 70,000-square-foot facility opened in 2022, and its services extend beyond core bioanalysis into comprehensive biospecimen management, biorepository services, and clinical trial kitting tailored to each phase of a study. KCAS Bio has developed more than 6,200 proprietary and non-proprietary assays and completed more than 25 FDA regulatory audits without a major finding, operating laboratory facilities across the US and Europe alongside a strategic alliance with Crux Biolabs in Australia. The company is the only bioanalytical laboratory with globally harmonized Cytek spectral flow cytometers across its US, EU, and Australian sites, supporting consistent data quality for sponsors running multi-region trials.

LabConnect

LabConnect provides central laboratory services and Functional Service Provider (FSP) solutions for clinical trials, coordinating sample-related activities including custom lab kits, sample tracking, global logistics, and a testing menu spanning more than 10,200 validated assays. Headquartered in Johnson City, Tennessee with more than 20 years of experience and roughly 2,000 clinical studies completed across 93 countries, the company opened a new China headquarters in Wuxi's National Hi-Tech District in March 2026 under CEO Wes Wheeler, extending its footprint into a major biomedicine hub. LabConnect's scientific team supports pre-clinical and clinical studies with biospecimen management, biomarker strategy, and next-generation biorepository services, alongside data management work integrating complex, multi-source datasets into submission-ready formats. The company expanded its API-integrated partnership with clinical inventory platform Slope in late 2025, supporting multiple clinical trials launched that quarter.

Oximio

Oximio was founded in Ukraine in 2004 and has grown into a global supply chain provider for the clinical research industry, now headquartered in the UK with a network of owned depots and customs-bonded warehouses spanning Europe, the Middle East, Africa, Latin America, and Asia-Pacific. The company's services include GDP-compliant cold-chain and ambient storage, comparator sourcing, importer of record support, and biospecimen reverse logistics, backed by a workforce of more than 300 multinational employees. Oximio opened Oximio Kenya in 2021 as a customs-bonded depot gateway into sub-Saharan Africa, part of a broader push to improve clinical trial supply access across the continent's historically underserved markets. In October 2025, the company acquired Bay Area Research Logistics (BARL) in Canada, rebranding it as Oximio BARL Canada and extending its network into North America, following the company's 2024 entry into the UK market with an MHRA Wholesale Distribution Authorisation license.

Tasso

Tasso was founded in 2011 by bioengineers Ben Casavant and Erwin Berthier, who developed the company's first patient-centric blood collection device in Casavant's living room before eventually taking the company through the Techstars healthcare accelerator and securing early DARPA grant funding. The Seattle-based company's devices, including the Tasso-M20, Tasso+, and Tasso Mini, use a push-button mechanism to collect capillary blood samples without the venipuncture or painful finger sticks traditional collection methods require, and have shipped more than one million units. In February 2025, Tasso launched its next-generation Tile-T20 dried blood spot cartridge paired with the Tasso Mini device, aimed at further simplifying at-home sample collection for both clinical trials and sports anti-doping testing. The company's blood-collection products have been used in trials run by Pfizer, Eli Lilly, and Merck, and Tasso has raised more than $131 million to date from investors including RA Capital, Cedars-Sinai, and the Merck Global Innovation Fund.

Explore the full Sample Logistics & Biobanking landscape

The companies above represent a portion of a much larger field.

Diligent's platform includes over 165 Sample Logistics & Biobanking Vendors, many with Vendor qualification data available on demand. Book a demo to explore Diligent's full vendor discovery database.

This article is intended as an informational overview of vendors operating in this space. Inclusion on this list does not constitute an endorsement, recommendation, or qualification by Diligent.